---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-030140"
form_type: "8-K"
ticker: "INBS"
cik: "0001725430"
company_name: "INTELLIGENT BIO SOLUTIONS INC."
filed_at: "2023-08-25T23:59:59+00:00"
generated_at: "2026-06-11T03:33:54.381491+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Intelligent Bio Solutions Q4 FY2023 revenue up 355% to $1.99M; net loss widens to $10.6M

## Summary
- Combined revenue & govt support income $1.99M (+355% YoY); product sales $1.26M.
- Net loss attributable to INBS $10.6M (vs $8.3M prior year); includes $4.2M goodwill impairment.
- Cash and equivalents $1.5M at June 30, 2023.
- Received FDA guidance for 510(k) pathway for its Intelligent Fingerprinting Drug Screening Cartridge.
- Expanded into Australia; secured 8 new customers; awarded 13th patent.

## SEC filing metadata
- accession: 0001493152-23-030140
- form_type: 8-K
- ticker: INBS
- cik: 0001725430
- company_name: INTELLIGENT BIO SOLUTIONS INC.
- filed_at: 2023-08-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725430/000149315223030140/0001493152-23-030140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725430/000149315223030140/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-030140
- JSON: https://secwatch.observer/filing/0001493152-23-030140.json
- Plain text: https://secwatch.observer/filing/0001493152-23-030140.txt

## Key facts
- Earnings Releases
  INTELLIGENT BIO SOLUTIONS INC. reported fiscal year ended June 30, 2023 results: revenue $1.99 million, net income $10.6 million loss.
  - Period: fiscal year ended June 30, 2023
  - Revenue: $1.99 million
  - Net income: $10.6 million loss
  - Result: reported results
  source text: The Company’s combined revenue and government support income increased by 355% to $1.99 million for the fiscal year ended June 30, 2023, including revenue from sales of goods of $1.26 million, compared to fiscal year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725430/000149315223030140/0001493152-23-030140-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.